Neurizon Therapeutics Limited (ASX:NUZ)
Australia · Delayed Price · Currency is AUD
0.0750
-0.0040 (-5.06%)
Mar 31, 2026, 3:44 PM AEST
Revenue by Segment
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | Jun '18 Jun 30, 2018 | Jun '17 Jun 30, 2017 | Jun '16 Jun 30, 2016 |
|---|
| 1.54M | 841.71K | 950.39K | 834.70K | 606.61K | | | | | |
Corporate & Research Growth | 82.70% | -11.43% | 13.86% | 37.60% | -24.89% | | | | | |
| - | - | 3.11M | 3.76M | 3.14M | | | | | |
Pharmaceutical - Epichem Growth | - | - | -17.15% | 19.82% | -9.08% | | | | | |
Inter-Segment Elimination | - | - | -163.51K | -82.03K | -71.31K | | | | | |
| 1.54M | 841.71K | 3.90M | 4.51M | 3.67M | | | | | |
| 82.70% | -78.42% | -13.53% | 22.85% | -10.96% | | | | | |
Revenue by Geography
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | Jun '18 Jun 30, 2018 | Jun '17 Jun 30, 2017 | Jun '16 Jun 30, 2016 |
|---|
| 17.28K | 1.04M | 1.13M | | | | | |
| -98.34% | -7.74% | -8.83% | | | | | |
| 2.69M | 1.74M | 685.01K | | | | | |
| 54.75% | 153.52% | -20.70% | | | | | |
| 100.44K | 181.70K | 114.24K | | | | | |
| -44.72% | 59.05% | -86.88% | | | | | |
| 18.76K | 96.09K | 210.59K | | | | | |
| -80.48% | -54.37% | -4.73% | | | | | |
| - | 323.85K | - | | | | | |
| 2.82M | 3.38M | 2.14M | | | | | |
| -16.48% | 57.98% | -33.03% | | | | | |
Source: S&P Global Market Intelligence.
